Medication info
Acetaminophen XR 50/500 mg Extended Release Tablet

Acetaminophen XR 50/500 mg Extended Release Tablet

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Anguk Pharmaceutical Co., Ltd.
Appearance
A bright blue, oval-shaped extended-release film-coated tablet with a bi-convex surface.
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202027 · Approved 2022.05.13 · Insurance code 650205940

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and not split, crushed, ground, or chewed. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose cannot be adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily, based on their current metformin dose, may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. As the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Anguk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps to control blood sugar levels in patients with type 2 diabetes through the combination of sitagliptin and metformin. It can effectively manage blood sugar levels when used in conjunction with dietary and exercise therapies, thereby improving blood sugar control and contributing to the prevention of diabetic complications.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and not split, crushed, ground, or chewed. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose cannot be adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily, based on their current metformin dose, may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. As the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication is used to treat diabetes and contains two components: sitagliptin and metformin. Firstly, a serious allergic reaction may rarely occur while taking this medication, so if you experience symptoms such as rash, difficulty breathing, or swelling of the face or neck, you should stop taking it immediately and consult a doctor. Secondly, this medication may cause pancreatitis, an inflammation of the pancreas. If symptoms such as abdominal pain, nausea, vomiting, or fever occur, immediate medical attention should be sought. Thirdly, due to the metformin component, there is a risk of lactic acidosis, a rare but serious metabolic disorder. If symptoms such as severe fatigue, muscle pain, difficulty breathing, abdominal pain, or confusion appear, you should go to the hospital immediately. Fourthly, patients with impaired kidney function or severe infections or dehydration should not take this medication, and if currently taking it, kidney function should be regularly monitored. Fifthly, this medication should not be administered to pregnant or breastfeeding women, and its safety has not been established for children under 18. Sixthly, during treatment with this medication, vigorous exercise, irregular meals, or interactions with other medications may lead to hypoglycemia; therefore, blood sugar levels should be checked frequently, and symptoms should be monitored closely. Seventhly, if you are undergoing surgery, you must discontinue this medication at least 48 hours prior and can only resume after confirming that kidney function has returned to normal post-surgery. Lastly, during treatment with this medication, regular blood tests and kidney function tests should be conducted, and since vitamin B12 levels may decrease, supplementation may be necessary if needed. It is important to follow the precautions mentioned above while taking this medication and to consult healthcare professionals immediately if any abnormal symptoms occur.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 16 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • blistering dermatosis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 to 30 degrees Celsius in room temperature conditions to preserve the medication's effectiveness.

Appearance and packaging

Appearance

A bright blue, oval-shaped extended-release film-coated tablet with a bi-convex surface.

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.